183 related articles for article (PubMed ID: 37531288)
1. Tixagevimab/cilgavimab for the prevention of COVID-19 in vaccine-refractory patients with autoimmune diseases: a prospective cohort study.
Minopoulou I; Tascilar K; Corte G; Mutlu MY; Schmidt K; Bohr D; Hartmann F; Manger K; Manger B; Korn K; Kleyer A; Simon D; Harrer T; Schett G; Fagni F
Rheumatology (Oxford); 2024 May; 63(5):1377-1383. PubMed ID: 37531288
[TBL] [Abstract][Full Text] [Related]
2. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Reimann P; Petzer V; Mündlein A; Hartmann B; Severgnini L; Winkler A; Lang T; Huynh M; Gasser K; Rüger J; Atzl M; Mink S; Fraunberger P; Schmidt S; Steiner N; Griesmacher A; Gunsilius E; Nachbaur D; Willenbacher W; Wolf D; Winder T; Benda MA
Ann Hematol; 2024 Jun; 103(6):2123-2131. PubMed ID: 38436671
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases.
Thomas M; Masson M; Bitoun S; Hamroun S; Seror R; Dupuy H; Lazaro E; Richez C; Allanore Y; Avouac J
Rheumatology (Oxford); 2024 May; 63(6):1632-1638. PubMed ID: 37632774
[TBL] [Abstract][Full Text] [Related]
5. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
Angotzi F; Petrella M; Berno T; Binotto G; Bonetto G; Branca A; Carraro M; Cavaretta CA; Cellini A; D'Amore F; Forlani L; Gianesello I; Gurrieri C; Imbergamo S; Lessi F; Maroccia A; Mazzetto F; Pavan L; Pezone S; Piazza F; Pravato S; Ruocco V; Scapinello G; Vianello F; Zambello R; Zatta I; Zoletto S; Padoan A; Trentin L; Visentin A
Front Oncol; 2023; 13():1212752. PubMed ID: 37427126
[TBL] [Abstract][Full Text] [Related]
6. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
[TBL] [Abstract][Full Text] [Related]
7. Tixagevimab/Cilgavimab does not prevent COVID-19 in patients with multiple sclerosis and related disorders on B-cell depleting therapies.
Conway S; Gupta S; Healy B; Chuang TY; Stazzone L; Sullivan J; Polgar-Turcsanyi M; Chitnis T; Houtchens M
Mult Scler Relat Disord; 2024 Jul; 87():105680. PubMed ID: 38795595
[TBL] [Abstract][Full Text] [Related]
8. Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies.
Leducq V; Zafilaza K; Fauchois A; Ghidaoui E; Sayon S; Dorival C; Meledje ML; Lusivika-Nzinga C; Yordanov Y; Martin-Blondel G; Carrat F; Marcelin AG; Soulie C
J Infect Dis; 2024 May; 229(5):1341-1351. PubMed ID: 37996072
[TBL] [Abstract][Full Text] [Related]
9. Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?
Romero A; Laurent C; Lebourg L; Lemée V; Hanoy M; Le Roy F; Grange S; Lemoine M; Guerrot D; Bertrand D
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543747
[No Abstract] [Full Text] [Related]
10. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience.
Pulvirenti F; Garzi G; Milito C; Sculco E; Sciannamea M; Napoli A; Cinti L; Roberto P; Punziano A; Carrabba M; Piano Mortari E; Carsetti R; Antonelli G; Quinti I
Front Immunol; 2023; 14():1249462. PubMed ID: 37954618
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
Levin MJ; Ustianowski A; De Wit S; Beavon R; Thissen J; Seegobin S; Dey K; Near KA; Streicher K; Kiazand A; Esser MT
Infect Dis Ther; 2024 Jun; 13(6):1253-1268. PubMed ID: 38703336
[TBL] [Abstract][Full Text] [Related]
13. [Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].
Roppelt AA; Lebedkina MS; Chernov AA; Kruglova TS; Mukhina OA; Yukhnovskaya YD; Samedova FA; Mаrkina UA; Andrenova GV; Karaulov AV; Lysenko MA; Fomina DS
Ter Arkh; 2023 Feb; 95(1):78-84. PubMed ID: 37167118
[TBL] [Abstract][Full Text] [Related]
14. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
[TBL] [Abstract][Full Text] [Related]
15. Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study.
Nassar MK; Sabry A; Elgamal M; Zeid Z; Abdellateif Abdelghany D; Tharwat S
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138212
[No Abstract] [Full Text] [Related]
16. Breakthrough SARS-CoV-2 infections among recipients of tixagevimab-cilgavimab prophylaxis: A citywide real-world effectiveness study.
Lendacki FR; Li L; Forrest GN; Jordan L; Zelinski C; Black SR; Ison MG; Seo JY
Transpl Infect Dis; 2024 Feb; 26(1):e14194. PubMed ID: 37987112
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.
Huygens S; GeurtsvanKessel C; Gharbharan A; Bogers S; Worp N; Boter M; Bax HI; Kampschreur LM; Hassing RJ; Fiets RB; Levenga H; Afonso PM; Koopmans M; Rijnders BJA; Oude Munnink BB
Clin Infect Dis; 2024 Jun; 78(6):1514-1521. PubMed ID: 38445721
[TBL] [Abstract][Full Text] [Related]
18. Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
Hobbs FDR; Montgomery H; Padilla F; Simón-Campos JA; Kim K; Arbetter D; Padilla KW; Reddy VP; Seegobin S; Streicher K; Templeton A; Viani RM; Johnsson E; Koh GCKW; Esser MT
Infect Dis Ther; 2023 Sep; 12(9):2269-2287. PubMed ID: 37751015
[TBL] [Abstract][Full Text] [Related]
19. Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study.
Jakimovski D; Eckert SP; Mirmosayyeb O; Thapa S; Pennington P; Hojnacki D; Weinstock-Guttman B
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851227
[TBL] [Abstract][Full Text] [Related]
20. Nephrotic-range proteinuria: a potential risk factor for failure of tixagevimab-cilgavimab prophylaxis.
Al Jurdi A; El Mouhayyar C; Efe O; Jeyabalan A; Riella LV
J Nephrol; 2024 Jan; 37(1):141-147. PubMed ID: 37658973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
